Stock Price Quote

THEMIS MEDICARE LTD.

NSE : THEMISMEDBSE : 530199ISIN CODE : INE083B01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE211.302.8 (+1.34 %)
PREV CLOSE ( ) 208.50
OPEN PRICE ( ) 210.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 7486
TODAY'S LOW / HIGH ( )206.75 213.55
52 WK LOW / HIGH ( )131.34 266
NSE210.351.85 (+0.89 %)
PREV CLOSE( ) 208.50
OPEN PRICE ( ) 209.60
BID PRICE (QTY) 210.35 (68)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 35174
TODAY'S LOW / HIGH( ) 207.00 213.70
52 WK LOW / HIGH ( )132.6 263.85
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-05 1969
Management Info
Dinesh S Patel - Chairman Sachin D Patel - Managing Director
Registered Office

Address Plot No 69 A,G I D C Industrial Estate, ,
Vapi,
Gujarat-396195

Phone 0260-2431447/ 2430219

Email themis@themismedicare.com

Website www.themismedicare.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

16Apr Themis Medicare informs about complian
Themis Medicare has informed that it enclosed the Compliance Certificate..
08Apr Themis Medicare informs about certific
Themis Medicare has informed that it enclosed a Certificate under Regula..
12Mar Themis Medicare informs about newspape
In terms of Regulation 47 of the SEBI Listing Regulations, Themis Medica..
10Nov Themis Medicare launches novel Opioid
Themis Medicare has launched a novel Opioid Injectable Analgesic Remifen..
06Nov Themis Medicare informs about newspape
In terms of Regulations 47 of the SEBI Listing Regulations, Themis Medic..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit20.01432.94
Gross Profit 28.52 589.08
Operating Profit 86.33789.67
Net Sales 825.133543.23

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2542.60 (12.29%)
M.Cap ( in Cr)1570.82
Neuland Laboratories (BSE)
peergroup  7654.80 (1.79%)
M.Cap ( in Cr)9821.02
Mankind Pharma (BSE)
peergroup  2397.40 (5.05%)
M.Cap ( in Cr)96037.07
Sanofi India (BSE)
peergroup  8470.70 (0.89%)
M.Cap ( in Cr)19508.55
Solara Active Pharma (BSE)
peergroup  474.10 (12.15%)
M.Cap ( in Cr)1706.58

Shareholding Pattern

PROMOTERS 67.16%
NON-INSTITUTION 32.82%
FI/BANKS/INSURANCE 0.01%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Themis Medicare Ltd.

Themis Medicare Ltd. was incorporated in the year 1969. Its today's share price is 211.3. Its current market capitalisation stands at Rs 1944.81 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3543.23 Cr and Total Income of Rs.3658.28 Cr. The company's management includes Adam Demeter, Shishir Dalal, Reena Patel, Sangameshwar Iyer, Sachin D Patel, Rajneesh Anand, Manjul Sandhu, Bhaskar V Iyer, Hariharan Subramaniam, Vijay Agarwal, Dinesh S Patel.

It is listed on the BSE with a BSE Code of 530199 , NSE with an NSE Symbol of THEMISMED and ISIN of INE083B01024. It's Registered office is at Plot No 69 A,G I D C Industrial Estate, Vapi-396195, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Krishaan & Co, MT Ankleshwaria & Co, RP Sardar & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.